Strive Health Welcomes Chief People Officer
David Thornton


Specialized kidney care company Strive Health announced that David Thornton is joining the company as Chief People Officer.

In this role, he will lead the company’s initiatives for attracting, developing, and retaining talent throughout the employee experience. Employee engagement will be a priority along with scaling the culture to support company growth.

“As Strive continues its mission to transform kidney care, we need a strong team in place to enhance the patient journey,” said Chris Riopelle, Chief Executive Officer of Strive Health. “We are growing rapidly, especially our field clinical teams, and need someone to lead this expansion in a way that protects and scales our culture, nurturing our team members as we work to improve patient outcomes and experiences. We are excited to welcome David.”

David joins Strive from Evolent Health, where he served as Chief Talent Officer, helping expand the company from 20 to over 3,500 people with an award-winning culture. Previously, he was with AOL for eight years. During this time, the company shifted to a media and advertising company, undergoing a significant cultural change. David brings extensive experience driving corporate values, culture and growth and will be instrumental to Strive Health’s ongoing success.

“Top companies are often the result of the right team being in place and driving the right mission forward,” said Thornton. “Strive holds that combination, along with a strong mission-driven culture for advancing the care patients receive while managing a complex and chronic disease. I am excited to join the Strive team, support its mission of advancing kidney care, and help solidify the company’s position as a top place for talent in healthcare.”

As kidney disease is the nation’s ninth-leading cause of death, a proactive, value-based approach to kidney care is critical to patient health and well-being. Strive integrates technology and clinical infrastructure to improve health outcomes for patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD).